Cargando…

Reverse signalling of membrane TNF in human natural killer cells: a comparison of the effect of certolizumab pegol and other anti-TNF agents

Detalles Bibliográficos
Autores principales:	Fossati, Gianluca, Nesbitt, Andrew M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242229/ http://dx.doi.org/10.1186/1479-5876-9-S2-O3

Ejemplares similares

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays
por: Fossati, G, et al.
Publicado: (2010)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling
por: Boyer, Jean Frédéric, et al.
Publicado: (2016)

The effects of anti–TNF agents on the expansion of T helper-type 17 cells driven by lipopolysaccharide-stimulated monocytes
por: Fossati, Gianluca, et al.
Publicado: (2012)

3. Certolizumab pegol for BehÇet's flare in pregnancy: a case report
por: Piper, Madeleine, et al.
Publicado: (2017)

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
por: Carron, Philippe, et al.
Publicado: (2016)

Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis
por: Boulter, EL, et al.
Publicado: (2011)

The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007
por: Schwartz, David A
Publicado: (2008)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
por: Koarada, Syuichi, et al.
Publicado: (2015)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)

Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease
por: Rutgeerts, Paul, et al.
Publicado: (2007)

Rapid and sustained effect of anti-TNF treatment in patients with ADA2 deficiency
por: Caorsi, R, et al.
Publicado: (2015)

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

PReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
por: Tarkiainen, M, et al.
Publicado: (2013)

New mechanisms of action and signaling by TNF-α
por: Ivashkiv, Lionel B
Publicado: (2012)

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
por: Colombo, Elisabetta, et al.
Publicado: (2009)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
por: Blonski, Wojciech, et al.
Publicado: (2012)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
por: Wade, Janet R., et al.
Publicado: (2015)

Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
por: Bailey, Kathryn, et al.
Publicado: (2020)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
por: Sharon, Yael, et al.
Publicado: (2020)

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis
por: Meling, Maureen Tania, et al.
Publicado: (2021)

Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Anti-TNF antibody therapy induces IL-17 suppressing regulatory T cells in patients with rheumatoid arthritis
por: McGovern, Jenny, et al.
Publicado: (2012)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
por: Furst, D E, et al.
Publicado: (2015)

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
por: Hannech, Emna, et al.
Publicado: (2021)

Successful treatment of dissecting cellulitis with certolizumab pegol in a pregnant patient
por: Almuhanna, Nouf, et al.
Publicado: (2023)

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry
por: Harrold, Leslie R., et al.
Publicado: (2018)

TNF and anti-TNF agents in Behçet's disease
por: Calamia, KT
Publicado: (2003)

Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
por: Dinesen, Lotte, et al.
Publicado: (2007)

Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2007)

Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis
por: Rosa, J, et al.
Publicado: (2010)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
por: Soriano, Enrique R, et al.
Publicado: (2018)

Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
por: Dattola, Annunziata, et al.
Publicado: (2017)

Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
por: Marin, Josefina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gtu9tthg3umjsj15o7r6kk3qkg